Respiratory Pathogen Panels

Respiratory Pathogen Panel (RP)^ and NEW Respiratory Pathogen Panel 2 (RP2)*

GenMark's Respiratory Pathogen Panels identify the most common viral and bacterial organisms associated with upper respiratory infection. The new RP2 panel includes SARS-CoV-2, the pathogen that causes COVID-19.

Clinical Impact of Respiratory Tract Infections – More Than Just Flu

Respiratory infections cause more doctor visits and absences from school and work than any other illness.[1] It is estimated that ~10% of people in the U.S. and Europe are infected with influenza each year during flu season; globally resulting in about 3-5 million severe cases and 250,000-500,000 deaths every year.[2][3][4] However, it is not just influenza that can cause respiratory infections; in addition to the flu, there are approximately 500 million non–influenza respiratory infections occurring annually.[5]

Comprehensive Diagnosis Impacts Patient Care

The clinical presentation of respiratory pathogens, including SARS-CoV-2, is very similar, thus complicating proper diagnosis and appropriate patient management. The comprehensive design of the ePlex RP Panel and NEW RP2 Panel (with SARS-CoV-2) may help improve patient care by identifying pathogens that are often missed by traditional methods. Accurately determining the cause of infection has been shown to reduce length of stay and time in isolation.[6] Accurate diagnosis also improves patient cohorting and decreases the risk of hospital acquired infection.[7]

Accurate and rapid diagnosis of respiratory infections is now even more important as SARS-CoV-2 infections continue to rise and are expected to coincide with cold and flu season. Symptoms of COVID-19 are similar to those of influenza, RSV and the common cold; and in some cases, co-infections may occur[8]. The ePlex Respiratory Pathogen Panel 2 (RP2) test provides results for more than 20 pathogens, including SARS-CoV-2 in less than two hours.  Rapid diagnosis is especially important for people who are more likely to become seriously ill from complications or require hospitalization, including young children, adults 65 and older, pregnant women and those with compromised immune systems.  The Centers for Disease Control and Prevention endorses testing for other respiratory pathogens in addition to SARS-CoV-2 because they provide broader information for clinicians and public health officials in addition to helping labs process more tests while conserving precious testing materials.[8.9]

RP VIRAL TARGETS                                                              RP2 VIRAL TARGETS

  • Adenovirus
  • Coronavirus (229E, HKU1, NL63, OC43)
  • Human Metapneumovirus
  • Human Rhinovirus/Enterovirus
  • Influenza A
  • Influenza A H1
  • Influenza A H1-2009
  • Influenza A H3
  • Influenza B
  • Parainfluenza 1
  • Parainfluenza 2
  • Parainfluenza 3
  • Parainfluenza 4
  • Respiratory Syncytial Virus A
  • Respiratory Syncytial Virus B

RP BACTERIAL TARGETS

  • Chlamydia pneumoniae       
  • Mycoplasma pneumoniae
  • Adenovirus
  • Coronavirus (229E, HKU1, NL63, OC43)
  • SARS-CoV-2
  • Human Metapneumovirus
  • Human Rhinovirus/Enterovirus
  • Influenza A
  • Influenza A H1
  • Influenza A H1-2009
  • Influenza A H3
  • Influenza B
  • Parainfluenza 1
  • Parainfluenza 2
  • Parainfluenza 3
  • Parainfluenza 4
  • Respiratory Syncytial Virus A
  • Respiratory Syncytial Virus B

RP2 BACTERIAL TARGETS

  • Chlamydia pneumoniae       
  • Mycoplasma pneumoniae

 

The True Sample-to-Answer Solution®

^For in vitro diagnostic use

*The ePlex RP2 Panel is distributed according to section IV.C .2 (Notifications) of FDA’s policy for Coronavirus Disease-2019 Tests During the Public Health Emergency

To learn more about the Respiratory Pathogen Panels or to schedule a demonstration, contact us at 1.800.373.6767 or email us.

[1] Johns Hopkins Medicine Health Library. http://www.hopkinsmedicine.org/healthlibrary/conditions/pediatrics/upper_respiratory_infection_uri_or_common_cold_90,P02966 (accessed February 2016)
[2] http://www.cdc.gov/flu/about/qa/disease.htm
[3] European Centre for Disease Prevention and Control. Seasonal Influenza. http://www.ecdc.europa.eu/en/healthtopics/seasonal_influenza/Pages/index.aspx (accessed February 2016)
[4] World Health Organization. (2014). Seasonal Influenza Fact Sheet 211. http://www.who.int/mediacentre/factsheets/fs211/en/
[5] Fendrick A, et al. (2003) The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 163(4):487-94.
[6] Rogers, B. et al. 2015. Impact of a Rapid Respiratory Panel Test on Patient Outcomes. Archives of Pathology and Laboratory Medicine. 139:636‐641.
[7] R.M. Martinez, H.E.Ka, L.M. Scicchitano, and D.M. Wolk, Geisinger Health System, Department of Laboratory Medicine, Danville PA, Wilkes Univ., Wilkes-Barre, PA
[8] Kim, D, et al. (2020) Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. JAMA April 15, 2020. Doi:10.1001/jama.2020.6266.
[9] https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html

popup close button